# Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

> **NCT07528716** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 280 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SHR- A1811
- **DRUG:** PCbHP
- **DRUG:** SHR- A1811+ Pyrotinib

## Key facts

- **NCT ID:** NCT07528716
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07528716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07528716, "Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07528716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*